Skip to main content

Table 4 Frequency of MCID and remission outcomes at endline

From: Feasibility and acceptability of a novel telepsychiatry-delivered precision prescribing intervention for anxiety and depression

Outcome Type

Survey Basis

Eligible No. Sample/Ineligible

Reporting Outcome No. (%)

Study Sample

(n = 6248)

Reporting Outcome No. (%)

Ineligible (n = 7512)

Reporting Outcome No. (%)

Intent-to-Treat Sample

(n = 13,760)

p-value

V

MCID

PHQ-9 and/or GAD-7

6248/7512

5599 (90%)

4585 (61%)

10,184 (74%)

<.001

.32

MCID

PHQ-9

6248/7512

5031 (81%)

3911 (52%)

8942 (65%)

<.001

.30

MCID

GAD-7

6248/7512

4760 (76%)

3622 (48%)

8382 (61%)

<.001

.30

Remission

PHQ-9 and/or GAD-7

6248/7512

4716 (75%)

3341 (44%)

8057 (59%)

<.001

.31

Remission

PHQ-9

6005/7149

3785 (63%)

2385 (33%)

6170 (47%)

<.001

.30

Remission

GAD-7

5368/6634

3714 (69%)

2588 (39%)

6302 (53%)

<.001

.30

  1. P and V values are for chi-square comparison between study sample and ineligible sample. V = Cramer’s V (values between .2 and .4 are considered a moderate effect size [49])